View of ALEGLITAZAR – AN UPCOMING DUAL PPAR ALPHA/GAMMA AGONIST REDUCING THE MACRO VASCULAR RISKS ASSOCIATED WITH TYPE 2 DIABETES MELLITUS

Return to Article Details ALEGLITAZAR – AN UPCOMING DUAL PPAR ALPHA/GAMMA AGONIST REDUCING THE MACRO VASCULAR RISKS ASSOCIATED WITH TYPE 2 DIABETES MELLITUS Download Download PDF